HLS Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 86

Employees

  • Stock Symbol
  • HLS

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.54
  • (As of Friday Closing)

HLS Therapeutics General Information

Description

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.

Contact Information

Formerly Known As
Heritage Life Sciences
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 10 Carlson Court
  • Suite 701
  • Etobicoke, Ontario M9W 6L2
  • Canada
+1 (647)
Primary Industry
Pharmaceuticals
Stock Exchange
TSE
Vertical(s)
Corporate Office
  • 10 Carlson Court
  • Suite 701
  • Etobicoke, Ontario M9W 6L2
  • Canada
+1 (647)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HLS Therapeutics Stock Performance

As of 20-Nov-2026, HLS Therapeutics’s stock price is $2.54. Its current market cap is $78.7M with 30.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.54 $2.56 $2.46 - $3.75 $78.7M 30.9M 66.1K -$0.22

HLS Therapeutics Financials Summary

As of 30-Sep-2026, HLS Therapeutics has a trailing 12-month revenue of $56.9M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 119,759 154,069 135,145 166,531
Revenue 56,887 55,500 56,619 63,074
EBITDA 17,640 15,928 16,899 12,534
Net Income (6,878) (12,430) (19,655) (27,531)
Total Assets 120,768 137,529 159,904 209,060
Total Debt 41,025 49,822 66,450 87,621
Public Fundamental Data provided by Morningstar, Inc. disclaimer

HLS Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore HLS Therapeutics‘s full profile, request access.

Request a free trial

HLS Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of br
Pharmaceuticals
Etobicoke, Canada
86 As of 2026

Baudette, MN
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HLS Therapeutics Competitors (11)

One of HLS Therapeutics’s 11 competitors is ANI Pharmaceuticals, a Corporation company based in Baudette, MN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ANI Pharmaceuticals Corporation Baudette, MN
Apotex Health Formerly PE-Backed Toronto, Canada
GSK Corporation London, United Kingdom
Teva Pharmaceutical Industries Corporation Tel Aviv, Israel
Novartis Corporation Basel, Switzerland
You’re viewing 5 of 11 competitors. Get the full list »

HLS Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HLS Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore HLS Therapeutics‘s full profile, request access.

Request a free trial

HLS Therapeutics Acquisitions (1)

HLS Therapeutics’s most recent deal was a Merger/Acquisition with Automodular for . The deal was made on 12-Mar-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Automodular 12-Mar-2018 Merger/Acquisition Holding Companies
To view HLS Therapeutics’s complete acquisitions history, request access »

HLS Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 30, 2022

44.42 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,669

Rank

Percentile

Pharmaceuticals

Industry

of 895

Rank

Percentile

Pharmaceuticals

Subindustry

of 431

Rank

Percentile

To view HLS Therapeutics’s complete esg history, request access »

HLS Therapeutics FAQs

  • When was HLS Therapeutics founded?

    HLS Therapeutics was founded in 2014.

  • Where is HLS Therapeutics headquartered?

    HLS Therapeutics is headquartered in Etobicoke, Canada.

  • What is the size of HLS Therapeutics?

    HLS Therapeutics has 86 total employees.

  • What industry is HLS Therapeutics in?

    HLS Therapeutics’s primary industry is Pharmaceuticals.

  • Is HLS Therapeutics a private or public company?

    HLS Therapeutics is a Public company.

  • What is HLS Therapeutics’s stock symbol?

    The ticker symbol for HLS Therapeutics is HLS.

  • What is the current stock price of HLS Therapeutics?

    As of 20-Nov-2026 the stock price of HLS Therapeutics is $2.54.

  • What is the current market cap of HLS Therapeutics?

    The current market capitalization of HLS Therapeutics is $78.7M.

  • What is HLS Therapeutics’s current revenue?

    The trailing twelve month revenue for HLS Therapeutics is $56.9M.

  • Who are HLS Therapeutics’s competitors?

    ANI Pharmaceuticals, Apotex Health, GSK, Teva Pharmaceutical Industries, and Novartis are some of the 11 competitors of HLS Therapeutics.

  • What is HLS Therapeutics’s annual earnings per share (EPS)?

    HLS Therapeutics’s EPS for 12 months was -$0.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process